Gradon D. Knotts
Profile
Gradon D.
Knotts held several senior business development positions at various pharmaceutical companies including Xenogen Corp., Sunesis Pharmaceuticals, Inc., and Myrexis, Inc. He also served as Vice President of Regulatory Affairs and Quality at Talon Therapeutics, Inc. from 2008 to 2009.
Knotts earned a Master's in Business Administration from the University of Notre Dame and an undergraduate degree from Brigham Young University.
Former positions of Gradon D. Knotts
| Companies | Position | End |
|---|---|---|
| MYREXIS, INC. | Corporate Officer/Principal | - |
| VIRACTA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Xenogen Corp.
 Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Corporate Officer/Principal | - |
Talon Therapeutics, Inc.
 Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Corporate Officer/Principal | - |
Training of Gradon D. Knotts
| University of Notre Dame | Masters Business Admin |
| Brigham Young University | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| MYREXIS, INC. | Finance |
| Private companies | 3 |
|---|---|
Talon Therapeutics, Inc.
Talon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talon Therapeutics, Inc. is a biopharmaceutical company, which is engaged in the developing and commercializing new and differentiated cancer therapies. The firm is developing the Marqibo for the treatment of acute lymphoblastic leukemia and other blood cancers including lymphoma. Its Menadione topical lotion is a compound which is developed for the prevention and treatment of skin toxicity associated with epidermal growth factor receptor inhibitors. The company was founded by Mark J. Ahn in 2002 and is headquartered in San Mateo, CA. | Health Technology |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Xenogen Corp.
Xenogen Corp. Medical SpecialtiesHealth Technology Xenogen Corp. provides real time in-vivo imaging services and genetic modification technologies. Its products and technologies include an imaging system, software, and biological materials. Its solutions are designed to improve discovery and pre-clinical research in multiple therapeutic areas. The company was founded by Pamela Reilly Contag and Christopher H. Contag in 1995 and is headquartered in Alameda, CA. | Health Technology |
- Stock Market
- Insiders
- Gradon D. Knotts
